Inhibrx Biosciences Shares Outstanding History (INBX)
Inhibrx Biosciences reported 14.6M shares outstanding at the end of fiscal 2025.
View full Inhibrx Biosciences company overviewInhibrx Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 14.6M | 101,705 | +0.70% |
| 2024 | 2024-12-31 | 14.5M | −32.9M | −69.44% |
| 2023 | 2023-12-31 | 47.4M | 33.1M | +232.62% |
| 2022 | 2022-12-31 | 14.2M | — | — |
Inhibrx Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 14.7M | 233,006 | +1.61% |
| Q1 2026 | 2026-03-31 | 14.6M | 131,382 | +0.91% |
| Q4 2025 | 2025-12-31 | 14.6M | 101,705 | +0.70% |
| Q3 2025 | 2025-09-30 | 14.5M | 22,189 | +0.15% |
| Q2 2025 | 2025-06-30 | 14.5M | 0 | 0.00% |
| Q1 2025 | 2025-03-31 | 14.5M | — | — |
| Q4 2024 | 2024-12-31 | 14.5M | −32.9M | −69.44% |
| Q3 2024 | 2024-09-30 | 14.5M | — | — |
| Q2 2024 | 2024-06-30 | 14.5M | — | — |
| Q4 2023 | 2023-12-31 | 47.4M | — | — |
Inhibrx Biosciences shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Inhibrx Biosciences's shares outstanding moved from 14.2M to 14.6M, a change of 336,434. The latest reported quarter, Q2 2026, shows 14.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibrx Biosciences source filings ↗